Neuroprotective Agents (pharmacology) < Neuroprotective Agents (therapeutic use) < Neuroprotective Agents (toxicity)

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 51.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000018 (1999)	H D Rosas [États-Unis] ; W J Koroshetz ; B G Jenkins ; Y I Chen ; D L Hayden ; M F Beal ; M E Cudkowicz	Riluzole therapy in Huntington's disease (HD).
000631 (2001)	P J Reading [Royaume-Uni] ; A K Luce ; I G Mckeith	Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
000647 (2002)	Maria C. Obinu [France] ; Michel Reibaud ; Véronique Blanchard ; Saliha Moussaoui ; Assunta Imperato	Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
000B11 (2003)	P K Morrish	REAL and CALM: what have we learned?
000B50 (2003)	Gregor K. Wenning [Autriche] ; Felix Geser ; Michaela Stampfer-Kountchev ; François Tison	Multiple system atrophy: an update.
000B88 (2003)	Paul K. Morrish [Royaume-Uni]	How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
000C97 (2004)	Susan Hollán [Hongrie] ; Lászl Vécsei ; Kálmán Magyar	Adverse effects of dopamine potentiation by long-term treatment with selegiline.
000E08 (2004)	Carl E. Clarke [Royaume-Uni]	A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
001042 (2004)	Marina De Tommaso [Italie] ; Nicola Specchio ; Vittorio Sciruicchio ; Olimpia Difruscolo ; Luigi Maria Specchio	Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
001154 (2005)	Robert M. Silva [États-Unis] ; Chia-Yi Kuan ; Pasko Rakic ; Robert E. Burke	Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease.
001224 (2005)	C Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis]	Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
001556 (2006)	Kevin M. Biglan [États-Unis] ; Steven Schwid ; Shirley Eberly ; Karen Blindauer ; Stanley Fahn ; Tamar Goren ; Karl Kieburtz ; David Oakes ; Sandra Plumb ; Andrew Siderowf ; Matthew Stern ; Ira Shoulson	Rasagiline improves quality of life in patients with early Parkinson's disease.
001816 (2006)	Tanya Y. Gurevich [Israël] ; Herzel Shabtai ; Amos D. Korczyn ; Ely S. Simon ; Nir Giladi	Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
001930 (2007)	Norman Reynolds	Revisiting safety of minocycline as neuroprotection in Huntington's disease.
001B16 (2007)	Mark A. Stacy [États-Unis] ; Rodger J. Elble ; William G. Ondo ; Shu-Chen Wu ; Joseph Hulihan	Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor.
002006 (2008)	Carl E. Clarke [Royaume-Uni]	Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
002132 (2008)	Maria Stamelou [Allemagne] ; Alexander Reuss ; Ulrich Pilatus ; Jörg Magerkurth ; Petra Niklowitz ; Karla M. Eggert ; Andrea Krisp ; Thomas Menke ; Carmen Schade-Brittinger ; Wolfgang H. Oertel ; Günter U. Höglinger	Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.
002190 (2008)	Paolo Barone [Italie] ; David J. Burn ; Teus Van Laar ; Chuanchieh Hsu ; Werner Poewe [Autriche] ; Roger M. Lane	Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
002380 (2008)	C Warren Olanow [États-Unis] ; Robert A. Hauser ; Joseph Jankovic [États-Unis] ; William Langston ; Anthony Lang ; Werner Poewe [Autriche] ; Eduardo Tolosa ; Fabrizio Stocchi ; Eldad Melamed ; Eli Eyal ; Olivier Rascol	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
002433 (2009)	Roger Lane [États-Unis] ; Yunsheng He ; Christopher Morris ; James B. Leverenz ; Murat Emre ; Clive Ballard	BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.
002483 (2009)	Robert G. Hart [États-Unis] ; Lesly A. Pearce ; Bernard M. Ravina ; Toby C. Yaltho ; John R. Marler	Neuroprotection trials in Parkinson's disease: systematic review.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Neuroprotective Agents (therapeutic use)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Neuroprotective Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective Agents (therapeutic use)
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024